BioNTech (BNTX) Competitors

BioNTech (NASDAQ:BNTX) and GSK (NYSE:GSK) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, valuation, institutional ownership, media sentiment and earnings.

Which has more volatility & risk, BNTX or GSK?

BioNTech has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500. Comparatively, GSK has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500.

Do analysts rate BNTX or GSK?

BioNTech presently has a consensus price target of $135.80, suggesting a potential upside of 33.13%. GSK has a consensus price target of $37.38, suggesting a potential downside of 5.65%. Given BioNTech's stronger consensus rating and higher possible upside, equities analysts plainly believe BioNTech is more favorable than GSK.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	0 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.76
GSK	1 Sell rating(s)	6 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.86

Do insiders and institutionals hold more shares of BNTX or GSK?

15.5% of BioNTech shares are owned by institutional investors. Comparatively, 15.7% of GSK shares are owned by institutional investors. 19.2% of BioNTech shares are owned by company insiders. Comparatively, 10.0% of GSK shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Does the media refer more to BNTX or GSK?

In the previous week, GSK had 30 more articles in the media than BioNTech. MarketBeat recorded 41 mentions for GSK and 11 mentions for BioNTech. BioNTech's average media sentiment score of 1.21 beat GSK's score of 0.60 indicating that BioNTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	7 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
GSK	14 Very Positive mention(s)	5 Positive mention(s)	10 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

Which has higher earnings and valuation, BNTX or GSK?

GSK has higher revenue and earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$2.98B	8.24	-$719.92M	-$1.60	-63.76
GSK	$31.63B	2.55	$3.29B	$2.16	18.34

Is BNTX or GSK more profitable?

GSK has a net margin of 10.81% compared to BioNTech's net margin of -12.20%. GSK's return on equity of 49.22% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-12.20%	-1.84%	-1.59%
GSK	10.81%	49.22%	11.31%

Summary

GSK beats BioNTech on 9 of the 16 factors compared between the two stocks.